HC Wainwright Boosts Earnings Estimates for Tyra Biosciences

Tyra Biosciences, Inc. (NASDAQ:TYRA) – HC Wainwright lifted their FY2026 EPS estimates for Tyra Biosciences in a research note issued to investors on Tuesday, September 22nd. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($2.60) for the year, up from their prior forecast of ($2.86). HC Wainwright currently has a “Buy” rating and a $29.00 price objective on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2026 earnings at ($0.62) EPS, Q1 2027 earnings at ($0.56) EPS, Q2 2027 earnings at ($0.57) EPS, Q3 2027 earnings at ($0.57) EPS, Q4 2027 earnings at ($0.58) EPS and FY2027 earnings at ($2.27) EPS.

Several other research firms have also issued reports on TYRA. Oppenheimer reissued an “outperform” rating and set a $40.00 target price (down from $50.00) on shares of Tyra Biosciences in a research note on Tuesday. Jefferies Financial Group reissued a “buy” rating and set a $42.00 price target on shares of Tyra Biosciences in a research report on Wednesday, August 5th. Wedbush reissued an “outperform” rating and issued a $53.00 price objective on shares of Tyra Biosciences in a research note on Thursday, September 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. Finally, Bank of America upped their target price on shares of Tyra Biosciences from $37.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Tyra Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $46.89.

Tyra Biosciences Stock Down 9.2%

NASDAQ:TYRA opened at $23.23 on Thursday. Tyra Biosciences has a 52 week low of $12.40 and a 52 week high of $40.65. The stock’s fifty day moving average is $27.19 and its two-hundred day moving average is $31.33. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -9.68 and a beta of 0.73.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04).

Hedge Funds Weigh In On Tyra Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in TYRA. Tidal Investments LLC acquired a new position in shares of Tyra Biosciences during the second quarter worth $943,000. WINTON GROUP Ltd acquired a new position in shares of Tyra Biosciences in the 2nd quarter valued at $537,000. Engineers Gate Manager LP purchased a new position in shares of Tyra Biosciences in the 2nd quarter valued at $1,021,000. Squarepoint Ops LLC raised its stake in Tyra Biosciences by 211.3% during the 2nd quarter. Squarepoint Ops LLC now owns 63,805 shares of the company’s stock worth $2,038,000 after acquiring an additional 43,311 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Tyra Biosciences during the 2nd quarter worth $334,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for diseases with limited treatment options. The company uses its proprietary SNÅP platform to design small-molecule therapies intended to selectively target disease-driving genetic alterations while addressing resistance mechanisms that can reduce the effectiveness of existing treatments.

Tyra’s lead programs are directed at fibroblast growth factor receptor (FGFR) biology. TYRA-300 is an oral, selective FGFR3 inhibitor being developed for conditions including FGFR3-altered urothelial cancer and achondroplasia, a genetic skeletal disorder.